At the 2024 Telstra Best of Business Awards in February, Earworx was recognised as the National Championing Health Award winner. Lisa Hellwege, the Clinical Director and Founder of Earworx, expressed her gratitude to the entire team and their patients for their trust and support. Earworx specialises in providing professional earwax removal services led by trained nurses using a procedure called microsuction.
Having identified a gap in the market for safe and gentle earwax removal services in her local community, Lisa started Earworx as a part-time venture alongside her role at the Royal Hobart Hospital. Over time, the business grew, and she transitioned to running it full-time, overcoming various challenges along the way, including the impact of COVID-19 and navigating the regulatory environment.
The recognition received at the Telstra Best of Business Award was a meaningful validation of Earworx’s efforts. It not only bolstered the business’s already strong reputation but also provided a boost to its branding, according to Hellwege.
Describing the rigorous application process, including extensive submissions and nerve-wracking presentations, Hellwege acknowledged that it provided invaluable insights into their own business.
Looking ahead, Earworx aims to raise awareness about the vital role of registered nurses in supporting the Australian healthcare system and addressing its challenges. The business plans to continue its mission of delivering high-quality, nurse-led earwax removal services while advocating for recognition and support from funding bodies.
You Might also like
-
Expansion of specialist training in regional & rural areas
Associate Professor Sanjay Jeganathan, Chair of the Council of Presidents of Medical Colleges (CPMC) states, ”Our rural and regional communities deserve the same access to specialist care as our cities. We’re seeing real results from our colleges’ commitment to rural training.”
-
AHHA Sidney Sax Medal 2019 Awarded to Vicki Wade
AHHA Sidney Sax Medal 2019 awarded to Vicki Wade
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.